Literature DB >> 27158372

VEGFR-3 blocking deteriorates inflammation with impaired lymphatic function and different changes in lymphatic vessels in acute and chronic colitis.

Xiao-Lei Wang1, Jing Zhao1, Li Qin1, Jing-Li Cao1.   

Abstract

BACKGROUND: Recent studies show inflammation-associated lymphangiogenesis (IAL) induced by vascular endothelial growth factor receptor 3 (VEGFR-3) pathway has a close relationship with chronic intestinal inflammation, and antilymphatic signaling pathways may repress IAL. However, whether the biologic function of lymphatic vessel is the same in severe acute intestinal inflammation still remain unknown.
METHODS: C57BL/6 mice were administered with 5% of dextran sodium sulfate (DSS) in drinking water for 7 days to establish severe acute colitis (SAC) model. Chronic colitis (CC) model was established by three cycles of 2% DSS for 5 days following water for 5 days. Mice were treated with VEGFR-3 antibody once daily in SAC group, or once every 3 days in CC group. The colon inflammation, submucosal edema, lymphatic vessel (LV) density, LV size, lymph flow, cytokines and immune cells infiltration were detected.
RESULTS: Both acute and chronic colitis resulted in a significant aggravation of colon inflammation in anti-VEGFR-3-treated mice, compared with PBS-treated colitis mice. Meanwhile, this was accompanied with decreased lymph drainage, increased submucosal edema, inflammatory cells infiltration and cytokines levels. In acute intestinal inflammation, significantly distorted and enlarged lymphatics were found but the LV number remained unchanged; not only significantly distorted and enlarged lymphatics but reduced LV number were found in chronic colitis.
CONCLUSION: Blocking VEGFR-3 in acute and chronic colitis leads to deterioration of colon inflammation with impaired lymphatic function and different changes in LVs. In the therapy targeting VEGF-C/VEGFR-3 pathway for lymphangiogenesis, the phrase and severity of intestinal inflammation should be taken into account.

Entities:  

Keywords:  Lymphangiogenesis; acute colitis; chronic colitis; vascular endothelial growth factor receptor 3

Year:  2016        PMID: 27158372      PMCID: PMC4846929     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  26 in total

1.  Blockade of VEGF receptor-3 aggravates inflammatory bowel disease and lymphatic vessel enlargement.

Authors:  Giorgia Jurisic; John P Sundberg; Michael Detmar
Journal:  Inflamm Bowel Dis       Date:  2013-08       Impact factor: 5.325

2.  IL-33 attenuates development and perpetuation of chronic intestinal inflammation.

Authors:  Philipp Groβ; Kristina Doser; Werner Falk; Florian Obermeier; Claudia Hofmann
Journal:  Inflamm Bowel Dis       Date:  2012-04-16       Impact factor: 5.325

3.  Lymphangiogenesis-independent resolution of experimental edema.

Authors:  Emily L Ongstad; Echoe M Bouta; Jaclynn E Roberts; Joseph S Uzarski; Sara E Gibbs; Michael S Sabel; Vincent M Cimmino; Melissa A Roberts; Jeremy Goldman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-03-05       Impact factor: 4.733

Review 4.  Emerging roles of lymphatics in inflammatory bowel disease.

Authors:  J Steven Alexander; Ganta Vijay Chaitanya; M B Grisham; Moheb Boktor
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

5.  Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer.

Authors:  Kenji Shimizu; Hajime Kubo; Koji Yamaguchi; Kazuhiko Kawashima; Yoshihide Ueda; Koichi Matsuo; Masaaki Awane; Yasuyuki Shimahara; Arimichi Takabayashi; Yoshio Yamaoka; Seiji Satoh
Journal:  Cancer Sci       Date:  2004-04       Impact factor: 6.716

6.  Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis.

Authors:  Ruolin Guo; Quan Zhou; Steven T Proulx; Ronald Wood; Rui-Cheng Ji; Christopher T Ritchlin; Bronislaw Pytowski; Zhenping Zhu; Yong-Jun Wang; Edward M Schwarz; Lianping Xing
Journal:  Arthritis Rheum       Date:  2009-09

7.  Dextran sulfate sodium (DSS)-induced colitis in mice.

Authors:  Benoit Chassaing; Jesse D Aitken; Madhu Malleshappa; Matam Vijay-Kumar
Journal:  Curr Protoc Immunol       Date:  2014-02-04

8.  VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease.

Authors:  Silvia D'Alessio; Carmen Correale; Carlotta Tacconi; Alessandro Gandelli; Giovanni Pietrogrande; Stefania Vetrano; Marco Genua; Vincenzo Arena; Antonino Spinelli; Laurent Peyrin-Biroulet; Claudio Fiocchi; Silvio Danese
Journal:  J Clin Invest       Date:  2014-08-08       Impact factor: 14.808

9.  VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis.

Authors:  Franco Scaldaferri; Stefania Vetrano; Miquel Sans; Vincenzo Arena; Giuseppe Straface; Egidio Stigliano; Alessandro Repici; Andreas Sturm; Alberto Malesci; Julian Panes; Seppo Yla-Herttuala; Claudio Fiocchi; Silvio Danese
Journal:  Gastroenterology       Date:  2008-10-07       Impact factor: 22.682

10.  Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis.

Authors:  Yutao Yan; Vasantha Kolachala; Guillaume Dalmasso; Hang Nguyen; Hamed Laroui; Shanthi V Sitaraman; Didier Merlin
Journal:  PLoS One       Date:  2009-06-29       Impact factor: 3.240

View more
  5 in total

1.  Lymphatic deletion of calcitonin receptor-like receptor exacerbates intestinal inflammation.

Authors:  Reema B Davis; Daniel O Kechele; Elizabeth S Blakeney; John B Pawlak; Kathleen M Caron
Journal:  JCI Insight       Date:  2017-03-23

Review 2.  Targeting Lymphatics for Nanoparticle Drug Delivery.

Authors:  Jacob McCright; Ritika Naiknavare; Jenny Yarmovsky; Katharina Maisel
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

Review 3.  Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review.

Authors:  Michael Yamakawa; Susan J Doh; Samuel M Santosa; Mario Montana; Ellen C Qin; Hyunjoon Kong; Kyu-Yeon Han; Charles Yu; Mark I Rosenblatt; Andrius Kazlauskas; Jin-Hong Chang; Dimitri T Azar
Journal:  Med Res Rev       Date:  2018-03-12       Impact factor: 12.944

4.  Meningeal lymphatics clear erythrocytes that arise from subarachnoid hemorrhage.

Authors:  Jinman Chen; Linmei Wang; Hao Xu; Lianping Xing; Zixin Zhuang; Yangkang Zheng; Xuefei Li; Chinyun Wang; Shaohua Chen; Zibin Guo; Qianqian Liang; Yongjun Wang
Journal:  Nat Commun       Date:  2020-06-22       Impact factor: 14.919

5.  ADSCs stimulated by VEGF-C alleviate intestinal inflammation via dual mechanisms of enhancing lymphatic drainage by a VEGF-C/VEGFR-3-dependent mechanism and inhibiting the NF-κB pathway by the secretome.

Authors:  Lei Zhang; Chen Ye; Peng Li; Chuanding Li; Weigang Shu; Yujie Zhao; Xiaolei Wang
Journal:  Stem Cell Res Ther       Date:  2022-09-05       Impact factor: 8.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.